CES2A-IN-2
CES2A-IN-2 (compound 14n) is an orally active, highly specific, irreversible and covalent CES2A inhibitor with an IC50 of 0.04 nM for human CES2A. CES2A-IN-2 covalently binds to CES2A by specifically targeting the catalytic serine residue (Ser-228). CES2A-IN-2 can significantly ameliorate Irinotecan-triggered gut toxicity (ITGT) without diminishing the anti-tumor effects of Irinotecan in tumor-bearing mice[1].
Product Specifications
UNSPSC
12352005
Target
Carboxylesterase (CES)
Related Pathways
Metabolic Enzyme/Protease
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Cancer; Metabolic Disease
Smiles
COC1=C(OC(N(CC)C)=O)C=CC(C(N2CCC(CC3=CC=CC=C3)CC2)=O)=C1
Molecular Formula
C24H30N2O4
Molecular Weight
410.51
References & Citations
[1]Zhipei Sang, et al. AI-Driven Discovery of Highly Specific and Efficacious hCES2A Inhibitors for Ameliorating Irinotecan-Triggered Gut Toxicity. J Med Chem. 2025 Mar 27;68 (6) :6252-6269.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
CES1; CES2
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC470679-500 1x 500 µL
CD171 / L1CAM (L1 Cell Adhesion Molecule) (UJ127), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC742216-500 1x 500 µL
CD50 / ICAM3 (CG106), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC940965-100 1x 100 µL
MUC1 / CA15-3 / EMA / CD227 (Epithelial Marker) (VU-11D1), CF594 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
